DIXI medical: Now Exclusively in Direct Sales in the United States

Closer to Clinicians: DIXI Medical’s New Chapter in the U.S. As of January 2026, DIXI Medical has successfully completed its transition to an exclusive direct sales model in the United States. This change marks a major milestone in our global mission to advance epilepsy care by working hand-in-hand with the clinical teams who trust our solutions. Why Direct Sales?. Operating directly in the U.S. market allows us to deliver a more responsive and personalized experience for healthcare institutions. Key benefits include:. Unmatched Support: Direct access to our highly motivated and experienced clinical support team., Competitive Pricing: A streamlined supply chain that delivers better value to hospitals and surgery centers., Faster Innovation: A direct feedback loop between U.S. surgeons and our R&D teams to accelerate the development of next-generation epilepsy tools., Seamless Access: Immediate availability of our full portfolio, including the MICRODEEP® PIXEL and the new SEEG-Tx® system. A Growing Team and Mission. Under the leadership of Krisahn Gren , Vice President of Sales for the U.S., we have built a national team dedicated to transforming epilepsy care. "Operating exclusively through direct sales means we can provide unmatched service and strengthen partnerships with the clinicians who rely on our precision technology every day," says Gren. Commitment to Education. Our direct presence also strengthens our educational initiatives. In February 2026, we hosted the first-ever Pediatric SEEG course in South Carolina, and our flagship SEEG training programs continue to provide intensive, expert-led guidance for epilepsy surgery teams nationwide.